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Introduction {#sec006}
============

Adverse drug reactions (ADRs) have been defined by the World Health Organization (WHO) as "a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for modification of physiological function" \[[@pone.0230576.ref001]\]. In children, ADRs surveillance and documentation is crucial to monitor the safe use of the medications used in this population since, compared to adults, children may have higher vulnerability for experiencing ADRs because: **a)** clinical trials carried out in these population are scarce \[[@pone.0230576.ref002],[@pone.0230576.ref003]\]; **b)** unlicensed and off-label drugs are often prescribed \[[@pone.0230576.ref004]\]; **c)** there is the possibility of exposure to medications during prenatal stage and breastfeeding \[[@pone.0230576.ref005]\], **d)** children may react differently than adults to administered medications, which can be explained by changes in absorption, distribution, metabolism and excretion \[[@pone.0230576.ref006]\], and **e)** hospitalized pediatric patients can be administered more than 10 drugs during their stay \[[@pone.0230576.ref007],[@pone.0230576.ref008]\]. In the pediatrics setting, ADRs generate a significant impact on morbidity, mortality \[[@pone.0230576.ref009]--[@pone.0230576.ref011]\] and costs \[[@pone.0230576.ref012],[@pone.0230576.ref013]\]. Frequency in hospitalized children ranges from 1.5% to 18.1%, while in outpatients it ranges from 0.7% to 2.74%; in addition 0.2% to 5.8% result in hospitalization \[[@pone.0230576.ref014],[@pone.0230576.ref015]\]. On the other hand, 7.7% of reports received by the Uppsala Monitoring Center involve children \[[@pone.0230576.ref016]\].

In 1999, Mexico joined the WHO Programme for International Drug Monitoring \[[@pone.0230576.ref017]\] and, ever since, the National Pharmacovigilance Center (CNF--Centro Nacional de Farmacovigilancia) is responsible for coordinating pharmacovigilance activities in the country, supported by an organization in which the Institutional Pharmacovigilance Centers (CIF--Centros Institucionales de Farmacovigilancia), the State Pharmacovigilance Centers and the Pharmaceutical Industry participate \[[@pone.0230576.ref018]\]. However, in spite of the above, studies in children are limited in Mexico \[[@pone.0230576.ref019]--[@pone.0230576.ref023]\] and there are no works reporting ADRs frequency and characteristics, as well as associated suspect medications, in pediatric hospital patients.

Aim of the study {#sec007}
----------------

To estimate the frequency and describe the characteristics (severity, seriousness, causality, management and outcomes) of ADRs occurred in Hospital Infantil de Mexico Federico Gómez (HIMFG) hospitalized patients, as well as to describe associated suspect drugs.

Methods {#sec008}
=======

Study design {#sec009}
------------

This study is a secondary analysis of the HIMFG Electronic Pharmacovigilance Program database from January 2014 to December 2017.

Study population and settings {#sec010}
-----------------------------

The study was conducted at HIMFG, which is a tertiary care pediatric hospital in Mexico with 229 registered beds. Hospital discharges during the study period ranged from 7,369 to 7,920 \[[@pone.0230576.ref024]\]. The HIMFG CIF designed the Electronic Pharmacovigilance Program for online ADR report filing from different hospitalization areas \[[@pone.0230576.ref025]\]. From January 2014 to December 2017, the Electronic Pharmacovigilance Program received 2,099 ADR reports, out of which 348 (16.6%) were excluded for belonging to a research protocol and one (0.05%) was a vaccine report.

Database and data collection {#sec011}
----------------------------

The data collected in the Electronic Pharmacovigilance Program included patient demographics, ADRs description, information on the suspect drug, information on concomitant pharmacotherapy, patient medical history and data of the personnel that generated the report \[[@pone.0230576.ref025]\]. The ADR reports were received at the HIMFG CIF, where a pharmacist analyzed them according to the Official Mexican Standard NOM-220-SSA1-2012, "Pharmacovigilance Implementation and Operation" \[[@pone.0230576.ref026]\]. A search for repeated cases was carried out using Microsoft Excel 2013 duplicate value identification tool; however, it is possible that some duplicate values were not detected. All reports were electronically submitted to the CNF using the SISCE v1.2.2014 database.

ADR reports quality {#sec012}
-------------------

The criteria to classify the completeness of the information contained in ADR reports was defined as \[[@pone.0230576.ref026]\]:

a.  Grade 0. When the report includes an identifiable patient, a suspected ADR and data on the reporter.

b.  Grade 1. When in addition to Grade 0 data, the date of ADR onset, as well as the dates of suspect drug initiation and discontinuation are included.

c.  Grade 2. When in addition to Grade 1 data, the name of the drug substance, the commercial name, dosage, route of administration and the reason for prescription of the suspect drug, as well as consequences of the event and medical history relevant data are included.

d.  Grade 3. When in addition to Grade 2 data, the reappearance of the clinical manifestation resulting from suspect drug re-administration is included (re-administration-positive).

ADRs frequency {#sec013}
--------------

To estimate ADRs overall frequency, the total number of patients with ADRs was divided by the total number of hospital discharges during the study period and the result was multiplied by 100.

Adverse drug reactions (ADRs) characteristics {#sec014}
---------------------------------------------

ADRs were defined according to the World Health Organization and the Official Mexican Standard NOM-220-SSA1-2012, "Pharmacovigilance Implementation and Operation" \[[@pone.0230576.ref001],[@pone.0230576.ref026]\]. ADRs were classified according to the WHO Adverse Drug Reaction Terminology (WHO-ART) catalog, which was integrated in the SISCE v1.2.2014 database. Each report was assessed for ADRs severity, seriousness and causality.

The ADRs severity classification was modified based on NOM-220-SSA1-2012 \[[@pone.0230576.ref026]\] as follows:

a.  Mild: ADRs not requiring pharmacological treatment or suspect drug discontinuation.

b.  Moderate: ADRs that require pharmacological treatment and no suspect drug discontinuation.

c.  Severe: ADRs that require both pharmacological treatment and suspect drug discontinuation.

The seriousness was classified as \[[@pone.0230576.ref026]\]:

a.  Serious ADRs: ADRs that: a) Result in patient death, b) Put patient's life in danger at the very moment they occur, c) Require hospitalization or prolongation of existing hospitalization, d) Result in persistent or significant disability or incapacity and e) Are the result of congenital anomalies or birth defects.

b.  Non-serious: ADRs not meeting the above-specified criteria.

Causality of each report was assigned using Naranjo's algorithm \[[@pone.0230576.ref027]\] as:

a.  Definite (≥ 9 points)

b.  Probable (5--8 points)

c.  Possible (1--4 puntos)

d.  Doubtful (≤ 0)

Management and outcomes {#sec015}
-----------------------

Patient management was reported as: **a)** ADR resulted in hospital admission, **b)** Medication was stopped because of ADRs, and **c)** ADR required treatment. Patient outcomes were reported as: **a)** Recovered without sequels, **b)** Recovered with sequels, **c)** Death (drug-related), **d)** Death (not drug-related) and **e)** Unknown (not documented in the report).

Drugs involved in ADRs {#sec016}
----------------------

The drugs involved in ADRs were categorized into various drug classes according to the Anatomical Therapeutic Chemical (ATC) classification, based on the 2018 WHO-ATC Index \[[@pone.0230576.ref028]\].

Data analyses {#sec017}
-------------

For descriptive purposes, patients were classified into 4 categories according to the body mass index (BMI) Z-score (normal weight, obesity, overweight and malnutrition) \[[@pone.0230576.ref029]\] and 3 categories according to age (infants, children and adolescents) \[[@pone.0230576.ref030]\]. The International Statistical Classification of Diseases, 10^th^ Revision (ICD 10), was used for all diagnoses \[[@pone.0230576.ref031]\]. The descriptive analyses included an estimation of relative frequencies for qualitative variables such as number of cases and percentages. The intra-group difference for categorical variables (age group, gender, body mass index category according to Z-score, type of diagnoses and location during the reaction) was calculated using the chi-square test. In all cases, a p-value \< 0.05 was considered to be statistically significant. Statistical analysis was performed using the SPSS 20 statistical package.

Ethical approval {#sec018}
----------------

The study was approved by the Hospital Infantil de Mexico Federico Gómez Research Commission, Ethics and Biosafety Committees with authorization number HIM 2018--003 SSA 1470. Patient confidentiality was protected in the SISCE v1.2.2014 database. Patient medical records were not reviewed in this research protocol. It is important mentioning that no information identifying the patients, such as names, initials or institutional registry number, will be disclosed in the publication or the available restriction-free database.

Results {#sec019}
=======

ADR reports quality {#sec020}
-------------------

A total of 1,750 ADR reports were reviewed, out of which 308 (17.6%) were grade 3, 1,341 (76.6%) grade 2 and 101 (5.8%) grade 0. Grade 0 reports were excluded because they did not have enough information for the analysis, and the results of this work are therefore based on 1,649 patient reports that contained 2,166 ADR clinical manifestations.

ADR frequency {#sec021}
-------------

The frequency of ADRs in 2014 was 8.07%, in 2015 it was 5.06%, in 2016 it was 6.52% and in 2017 it was 2.12% **([S1 Fig](#pone.0230576.s001){ref-type="supplementary-material"})**.

Patient demographics {#sec022}
--------------------

The age group with the highest ADR frequency was the group of children (2 to 11 years), with 56.9% (p \< 0.05). The female gender had an ADR frequency of 52%, whereas in males it was 48% (*p* \> 0.05). The highest ADR frequency was observed in patients with normal weight (46.6%), followed by patients with malnutrition (35.3%) (p \< 0.05). The main diagnoses were neoplasms (C00-D48) with 72.2%, followed by congenital malformations, deformities and chromosomal abnormalities (Q00-Q99) with 10.1% (p \< 0.05). The reports were mainly from Emergency Department patients (70.0%) (p \< 0.05) ([Table 1](#pone.0230576.t001){ref-type="table"}).

10.1371/journal.pone.0230576.t001

###### Patient demographics.

![](pone.0230576.t001){#pone.0230576.t001g}

                                                                                 Total number of patients n = 1,649 n (%)   *p* value
  ------------------------------------------------------------------------------ ------------------------------------------ --------------------------------------------
  **Age**                                                                                                                   
  Neonates (0 to 27 days)                                                        64 (3.9)                                   0.000[\*](#t001fn003){ref-type="table-fn"}
  Infants and toddlers (28 days to 23 months)                                    224 (13.6)                                 
  Children (2 to 11 years)                                                       939 (56.9)                                 
  Adolescents (12 to 18 years)                                                   384 (23.3)                                 
  Adults (≥ 18 years)                                                            16 (1)                                     
  No data                                                                        22 (1.3)                                   
  **Gender**                                                                                                                
  Females                                                                        857 (52)                                   0.109
  Males                                                                          792 (48)                                   
  **BMI Z-score**                                                                                                           
  Obesity                                                                        117 (7.1)                                  0.000[\*](#t001fn003){ref-type="table-fn"}
  Overweight                                                                     159 (9.7)                                  
  Normal weight                                                                  769 (46.6)                                 
  Malnutrition                                                                   582 (35.3)                                 
  No data                                                                        22 (1.3)                                   
  **Diagnoses**                                                                                                             
  C00-D48 Neoplasms                                                              1190 (72.2)                                0.000[\*](#t001fn003){ref-type="table-fn"}
  Q00-Q99 Congenital malformations, deformations and chromosomal abnormalities   167 (10.1)                                 
  J00-J99 Diseases of the respiratory system                                     46 (2.8)                                   
  D50-D89 Diseases of the blood                                                  45 (2.7)                                   
  K00-K93 Diseases of the digestive system                                       29 (1.8)                                   
  Z00-Z99 Factors influencing health status and contact with health services     24 (1.5)                                   
  I00-I99 Diseases of the circulatory system                                     23 (1.4)                                   
  N00-N99 Diseases of the genitourinary system                                   22 (1.3)                                   
  G00-G99 Diseases of the nervous system                                         21 (1.3)                                   
  A00-B99 Certain infectious and parasitic diseases                              18 (1.1)                                   
  Others[^a^](#t001fn001){ref-type="table-fn"}                                   49 (2.9)                                   
  No data                                                                        15 (0.9)                                   
  **Location during reaction**                                                                                              
  Emergency Department                                                           1153 (70.0)                                0.000[\*](#t001fn003){ref-type="table-fn"}
  Surgical Intensive Therapy Unit                                                178 (10.8)                                 
  Pediatric Intensive Therapy Unit                                               131 (7.9)                                  
  Neonatology Department                                                         84 (5.0)                                   
  Infectious Diseases Department                                                 41 (2.5)                                   
  Nephrology Department                                                          31 (1.9)                                   
  Others[^b^](#t001fn002){ref-type="table-fn"}                                   31 (1.9)                                   

^a^ Others: P00-P96 Certain conditions originating in the perinatal period, E00-E90 Endocrine, nutritional and metabolic diseases, M00-M99 Diseases of the musculoskeletal system and connective tissue, R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, F00-F99 Mental and behavioral disorders, S00-T98 Injury, poisoning and certain other consequences of external causes.

^b^Others: Adolescents Department, Gastroenterology Department, Anesthesiology Department, General Surgery Department, Allergy Department, Internal Medicine Department, Dermatology Department

*\*p* \< 0.05

Adverse drug reactions (ADRs) characteristics {#sec023}
---------------------------------------------

Among total reported ADRs, 14.4% were severe and 81.0% were serious. On the other hand, 58.6% of ADRs were probable, 38.9% possible, 2.1% definite and 0.4% doubtful. Patients not diagnosed with Neoplasms (C00-D48) had 14.9% of severe ADRs, 51.9% of non-serious ADRs y 78% of probable ADRs, whereas those diagnosed with Neoplasms (C00-D48) had 14.2% of severe ADRs, 95.7% of serious ADRs and 49.9% of probable ADRs ([Table 2](#pone.0230576.t002){ref-type="table"}).

10.1371/journal.pone.0230576.t002

###### Severity, seriousness and causality of total ADRs, ADRs in patients not diagnosed with Neoplasms and in patients diagnosed with Neoplasms.
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                    Total ADRs n = 2,166 n (%)   ADRs in patients without Neoplasms (C00-D48) n = 672 n (%)   ADRs in patients with Neoplasms (C00-D48) n = 1,494 n (%)
  ----------------- ---------------------------- ------------------------------------------------------------ -----------------------------------------------------------
  **Severity**                                   ** **                                                         
  Severe            312 (14.4)                   100 (14.9)                                                   212 (14.2)
  Moderate          1,699 (78.4)                 433 (64.4)                                                   1,266 (84.7)
  Mild              155 (7.2)                    139 (20.7)                                                   16 (1.1)
  **Seriousness**                                ** **                                                         
  Serious           1,753 (81.0)                 323 (48.1)                                                   1,430 (95.7)
  Non-serious       413 (19.0)                   349 (51.9)                                                   64 (4.3)
  **Causality**                                  ** **                                                         
  Definite          45 (2.1)                     23 (3.4)                                                     22 (1.5)
  Probable          1,270 (58.6)                 524 (78.0)                                                   746 (49.9)
  Possible          842 (38.9)                   122 (18.2)                                                   720 (48.2)
  Doubtful          9 (0.4)                      3 (0.4)                                                      6 (0.4)

The most common serious ADR was febrile neutropenia (52.4%) in patients diagnosed with Neoplasms (C00-D48) ([Table 3](#pone.0230576.t003){ref-type="table"}), while the most common non-serious ADR in patients not diagnosed with Neoplasms (C00-D48) was abnormal electrolytes (26.6%), ([Table 4](#pone.0230576.t004){ref-type="table"}).

10.1371/journal.pone.0230576.t003

###### 10 most common serious ADRs in all patients, in patients not diagnosed with Neoplasms and in patients diagnosed with Neoplasms.
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                                                                Serious ADRs in all patients n = 1,753 n (%)   Serious ADRs in patients without Neoplasms (C00-D48) n = 323 n (%)   Serious ADRs in patients with Neoplasms (C00-D48) n = 1,430 n (%)
  ------------------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------
  Febrile neutropenia                                           780 (44.5)                                     31 (9.6)                                                             749 (52.4)
  Sepsis                                                        147 (8.4)                                      7 (2.2)                                                              140 (9.8)
  Abnormal electrolytes[^a^](#t003fn001){ref-type="table-fn"}   134 (7.6)                                      99 (30.7)                                                            35 (2.4)
  Septic shock                                                  101 (5.8)                                      1 (0.3)                                                              100 (7.0)
  Pancytopenia                                                  98 (5.6)                                       4 (1.2)                                                              94 (6.6)
  Mucositis                                                     45 (2.6)                                       2 (0.6)                                                              43 (3.0)
  Pancreatitis                                                  27 (1.5)                                       5 (1.5)                                                              22 (1.5)
  Thrombocytopenia                                              23 (1.3)                                       4 (1.2)                                                              19 (1.3)
  Hypotension                                                   21 (1.2)                                       15 (4.6)                                                             6 (0.4)
  Neutropenic colitis                                           16 (0.9)                                       1 (0.3)                                                              15 (1.0)
  Others                                                        361 (20.6)                                     154 (47.7)                                                           207 (14.5)

^a^Abnormal electrolytes: Calcium deficiency, calcium depletion, decreased blood chloride, hyperphosphatemia, hypernatremia, hyperkalemia, hypocalcemia, hypochloremia, hypophosphatemia, hypokalemia, hypomagnesemia, hyponatremia, decreased serum potassium, increased serum potassium, decreased plasma sodium.

10.1371/journal.pone.0230576.t004

###### 10 most common non-serious ADRs in all patients, in patients not diagnosed with Neoplasms and in patients diagnosed with Neoplasms.
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                                                                Non-Serious ADRs in all patients n = 413 n (%)   Non-Serious ADRs in patients without Neoplasms (C00-D48) n = 349 n (%)   Non-Serious ADRs in patients with Neoplasms (C00-D48) n = 64 n (%)
  ------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------ --------------------------------------------------------------------
  Abnormal electrolytes[^a^](#t004fn001){ref-type="table-fn"}   108 (26.2)                                       93 (26.6)                                                                15 (23.4)
  Cutaneous eruption[^b^](#t004fn002){ref-type="table-fn"}      31 (7.5)                                         22 (6.3)                                                                 9 (14.1)
  Hyperglycemia                                                 30 (7.3)                                         27 (7.7)                                                                 3 (4.7)
  Tachycardia                                                   22 (5.3)                                         20 (5.7)                                                                 2 (3.1)
  Increased aspartate aminotransferase                          14 (3.4)                                         13 (3.7)                                                                 1 (1.6)
  Increased alanine aminotransferase                            12 (2.9)                                         11 (3.2)                                                                 1 (1.6)
  Vomiting                                                      12 (2.9)                                         11 (3.2)                                                                 1 (1.6)
  Fever                                                         10 (2.4)                                         8 (2.3)                                                                  2 (3.1)
  Hypotension                                                   10 (2.4)                                         9 (2.6)                                                                  1 (1.6)
  Nausea                                                        10 (2.4)                                         8 (2.3)                                                                  2 (3.1)
  Others                                                        154 (37.3)                                       127 (36.4)                                                               27 (42.1)

^a^Abnormal electrolytes: Calcium deficiency, calcium depletion, decreased blood chloride, hyperphosphatemia, hypernatremia, hyperkalemia, hypocalcemia, hypochloremia, hypophosphatemia, hypokalemia, hypomagnesemia, hyponatremia, decreased serum potassium, increased serum potassium, decreased plasma sodium.

^b^Cutaneous eruption: erythema, rash, urticaria, exanthema, erythema multiforme, pruritus.

Management and outcomes {#sec024}
-----------------------

In 70.3% of total patients, ADRs were the cause of hospital admission, 15.2% of the patients required the withdrawal of the suspect drug and 83.6% required treatment for ADRs. Recovery from the ADRs without sequelae was observed in 90.8% of patients; however 0.7% recovered with some sequel. On the other hand, in 1.1% of patients, death was related to the suspect drug. Among the patients diagnosed with Neoplasms (C00-D48), 91.9% required hospital admission due to ADRs, 47.3% of the patients not diagnosed with Neoplasms (C00-D48) required the withdrawal of the suspect drug, whereas 94.5% of patients with Neoplasms (C00-D48) required treatment for ADRs. Of the patients without Neoplasms (C00-D48), 1.1% recovered from the ADR with some sequel. On the other hand, in 1.4% of patients with Neoplasms (C00-D48), death was related to the suspect drug ([Table 5](#pone.0230576.t005){ref-type="table"}).

10.1371/journal.pone.0230576.t005

###### ADRs management and outcomes in all patients, in patients not diagnosed with Neoplasms (C00-D48) and in patients diagnosed with Neoplasms (C00-D48).
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                                             Total number of patients n = 1,649 n (%)   Patients without Neoplasms (C00-D48) n = 444 n (%)   Patients with Neoplasms (C00-D48) n = 1,190 n (%)   Undiagnosed patients n = 15 n (%)
  ------------------------------------------ ------------------------------------------ ---------------------------------------------------- --------------------------------------------------- -----------------------------------
  **ADRs resulting in hospital admission**                                                                                                                                                       
  Yes                                        1,160 (70.3)                               58 (13.1)                                            1,094 (91.9)                                        8 (53.3)
  No                                         489 (29.7)                                 386 (86.9)                                           96 (8.1)                                            7 (46.7)
  **Stopped the medication**                                                                                                                                                                     
  Yes                                        250 (15.2)                                 210 (47.3)                                           36 (3.0)                                            4 (26.7)
  No                                         1,399 (84.8)                               234 (52.7)                                           1,154 (97.0)                                        11 (73.3)
  **ADRs requiring treatment**                                                                                                                                                                   
  Yes                                        1,378 (83.6)                               244 (55.0)                                           1,124 (94.5)                                        10 (66.7)
  No                                         271 (16.4)                                 200 (45.0)                                           66 (5.5)                                            5 (33.3)
  **Outcomes**                                                                                                                                                                                   
  Recovered with no sequel                   1,498 (90.8)                               348 (78.4)                                           1,136 (95.5)                                        14 (93.3)
  Recovered with sequel                      11 (0.7)                                   5 (1.1)                                              6 (0.5)                                             0 (0.0)
  Death--drug-related                        18 (1.1)                                   1 (0.22)                                             17 (1.4)                                            0 (0.0)
  Death--not drug-related                    5 (0.3)                                    5 (1.1)                                              0 (0.0)                                             0 (0.0)
  Unknown                                    117 (7.1)                                  85 (19.2)                                            31 (2.6)                                            1 (6.7)

Kidney failure was the most common sequel in those patients who recovered with any ([Table 6](#pone.0230576.t006){ref-type="table"}). Febrile neutropenia was the ADR that most often occurred in patients whose death was related to the suspect drug ([Table 7](#pone.0230576.t007){ref-type="table"}).

10.1371/journal.pone.0230576.t006

###### Patients with "Recovered with sequel" outcome.
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  Patient data                 Diagnoses                             Sequel-associated ADR                                                                                                                              Sequel                             Suspect drug         Concomitant drugs
  ---------------------------- ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------- ----------------------------------------
  Female 15 years, 1 month     Nasopharyngeal carcinoma              Acute kidney failure                                                                                                                               Acute kidney failure               Cisplatin            None
  Female 12 years, 10 months   Acute lymphoblastic leukemia          Acute kidney failure, increased hepatic enzymes                                                                                                    Acute kidney failure               Methotrexate         None
  Female 17 years, 6 months    Serious mitral insufficiency          Serum electrolyte decrease (potassium, sodium, chloride), metabolic alkalosis, acute kidney failure (probable tubular necrosis), oliguria-anuria   Acute kidney failure               Furosemide           None
  Female 7 months              Heart failure                         Serum electrolyte decrease (potassium), acute kidney failure (tubular necrosis)                                                                    Acute kidney failure               Furosemide           Spironolactone
  Male 12 years, 10 months     Acute myeloid leukemia                Neutropenic colitis                                                                                                                                Hemicolectomy                      Cytarabine           Etoposide, mercaptopurine, doxorubicin
  Male 1 year, 2 months        Acute lymphoblastic leukemia          Febrile neutropenia, septic shock with abdominal focus                                                                                             Total colectomy                    Cytarabine           Etoposide
  Male 3 years, 1 month        Acute lymphoblastic leukemia          Lumbosacral area increased volume, abdominal pain                                                                                                  Lumbosacral region graft           Asparaginase         Dexamethasone, Vincristine,
  Female 3 years, 5 months     Biliary duct atresia, chicken pox     Gastrointestinal bleeding                                                                                                                          Varix ligation                     Ibuprofen            Acyclovir, propranolol, prednisone
  Female 2 months              Anorectal malformation with fistula   Low urinary output                                                                                                                                 Nephrocalcinosis                   Furosemide           Domperidone, spironolactone
  Female 13 years, 7 months    End-stage chronic renal disease       Hyperglycemia                                                                                                                                      Diabetes mellitus                  Methylprednisolone   None
  Male 11 years, 6 months      Right eye retinoblastoma              End-stage chronic kidney failure                                                                                                                   End-stage chronic kidney failure   Cisplatin            Cyclophosphamide, Vincristine

10.1371/journal.pone.0230576.t007

###### Patients with the "Death--drug-related" outcome.
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  Patient data                Diagnosis                      ADR associated with patient death                                                                                          Suspect drug   Concomitant drugs
  --------------------------- ------------------------------ -------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------------------
  Male 5 years, 2 months      Acute lymphoblastic leukemia   Febrile neutropenia, septic shock                                                                                          Cytarabine     Fludarabine, idarubicin
  Female 2 years, 10 months   Acute lymphoblastic leukemia   Febrile neutropenia, septic shock                                                                                          Methotrexate   None
  Female 17 years, 6 months   Hodgkin's lymphoma             Febrile neutropenia, septic shock \*\* Serum creatinine increase that brought the patient to hemodialysis                  Methotrexate   None
  Female 15 years, 1 month    Acute lymphoblastic leukemia   Febrile neutropenia, pancreatitis                                                                                          Asparaginase   Cyclophosphamide, Daunorubicin, Vincristine, Dexamethasone
  Female 8 years, 2 months    Acute lymphoblastic leukemia   Febrile neutropenia, pancreatitis                                                                                          Asparaginase   Daunorubicin, Vincristine
  Male 14 years, 6 months     Medulloblastoma                Neutropenic colitis, sepsis                                                                                                Vincristine    Irinotecan, temozolomide
  Female 10 years, 3 months   Acute lymphoblastic leukemia   Diabetes Mellitus, febrile neutropenia, septic shock                                                                       Vincristine    Daunorubicin, asparaginase
  Female 11 years, 6 months   Osteosarcoma                   Febrile neutropenia, septic shock                                                                                          Methotrexate   None
  Male No "age" data          Acute lymphoblastic leukemia   Febrile neutropenia, septic shock                                                                                          Cytarabine     Etoposide, daunorubicin
  Male 15 years, 6 months     Acute lymphoblastic leukemia   Febrile neutropenia, septic shock                                                                                          Cytarabine     Methotrexate
  Male 4 years, 11 months     Hepatoblastoma                 Febrile neutropenia, septic shock                                                                                          Doxorubicin    Cisplatin, fluorouracil, Vincristine
  Female 16 years, 1 month    Acute lymphoblastic leukemia   Mucositis, pancytopenia, septic shock, Stevens Johnson syndrome                                                            Methotrexate   Cytarabine
  Male 18 years, 10 months    Acute lymphoblastic leukemia   Febrile neutropenia, septic shock                                                                                          Methotrexate   None
  Female 15 years, 4 months   Rhabdomyosarcoma               Diarrhea, febrile neutropenia, septic shock                                                                                Irinotecan     Doxorubicin, cisplatin
  Female 7 years, 4 months    Hodgkin's lymphoma             Febrile neutropenia, decompensated mixed shock, pulmonary infection that required lung resection, multiple organ failure   Ifosfamide     Methotrexate, Etoposide, Dexamethasone
  Female 13 years, 9 months   Acute myeloid leukemia         Febrile neutropenia, hemorrhage                                                                                            Tretinoin      None
  Male 3 years, 5 months      Acute lymphoblastic leukemia   Chicken pox                                                                                                                Vincristine    Daunorubicin, Asparaginase, Dexamethasone
  Male 2 years, 4 months      Ventricular septal defect      Pulmonary hemorrhage                                                                                                       Heparin        None

Febrile neutropenia was the ADR that most resulted in hospital admissions ([Table 8](#pone.0230576.t008){ref-type="table"}).

10.1371/journal.pone.0230576.t008

###### Main ADRs resulting in hospital admission.
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                        n (%)
  --------------------- -------------
  Febrile neutropenia   774 (53.7%)
  Sepsis                190 (13.2%)
  Pancytopenia          97 (6.7%)
  Septic shock          57 (4.0%)
  Mucositis             45 (3.1%)

Drugs involved in ADRs {#sec025}
----------------------

The drugs that more often were involved in serious ADRs were group L medications (Antineoplastic and immunomodulating agents), with 81.2% ([S1 Table](#pone.0230576.s002){ref-type="supplementary-material"}), while the drugs that were most commonly related to non-serious ADRs were group C drugs (Cardiovascular system) with 34.9% ([S2 Table](#pone.0230576.s003){ref-type="supplementary-material"}).

Discussion {#sec026}
==========

To the best of our knowledge, the present study is the only one that has assessed ADRs causality, type, severity, seriousness and quality of ADR reports information in children from a tertiary care pediatric hospital in Mexico \[[@pone.0230576.ref014],[@pone.0230576.ref015],[@pone.0230576.ref032]--[@pone.0230576.ref035]\]. The ADR reports received at the CIF had sufficient information to carry out the analysis of this work, since 94.2% were grade 2 and grade 3, which was expected, since, in Mexico, hospitals are generators of the ADR reports with the best quality of information \[[@pone.0230576.ref036]\].

ADRs estimated frequency in the present study ranges from 2.12% to 8.07%, which is consistent with that reported in the literature \[[@pone.0230576.ref014],[@pone.0230576.ref015],[@pone.0230576.ref035]\]; however, these figures should be interpreted with caution, since: **a)** although doctors identify ADRs, they do not report them \[[@pone.0230576.ref037]\], which causes an underreporting of 93.9% \[[@pone.0230576.ref038]\] and, therefore, the magnitude of the problem is underestimated, and **b)** the methodologies used in the studies are different, which makes comparison between them difficult. On the other hand, variations in ADR frequency could be attributed to factors such as: **a)** under-reporting \[[@pone.0230576.ref038]\], since ADRs notification at HIMFG is voluntary; **b)** the CIF temporarily assigned pharmacy students to hospitalization areas in order for them to take care of reporting the ADRs experienced by patients, given that, at HIMFG, there are no clinical pharmacists who, among other things, are qualified to report ADRs; and **c)** one of the authors of this study (CCO) implemented, among the activities of the hematological oncology department residents, the report of ADRs experienced by patients diagnosed with any neoplastic disease.

The fact that ADRs occurred more often in the group of older patients (2 to 11 years and 12 to 18 years), in the female gender and in subjects diagnosed with neoplasms (C00-D48) can be explained by the fact that some of these variables have been confirmed as risk factors for ADRs in children \[[@pone.0230576.ref034],[@pone.0230576.ref039],[@pone.0230576.ref040]\], while malnutrition has also been associated with a high rate of ADRs in children diagnosed with neoplasms \[[@pone.0230576.ref041]\]. It is important mentioning that none of the above variables can be interpreted or be inferred as risk factors in the study population, since, due to its nature, the study has not that scope. ADRs occurred mainly in the Emergency Department, which could be attributed to the febrile neutropenia reaction induced by medications administered to patients with cancer diagnoses \[[@pone.0230576.ref042]\].

Severity (mild, moderate, severe) describes the intensity of a clinical manifestation in the patient, whereas seriousness is based on the outcome of the event or the associated action to treat it \[[@pone.0230576.ref001],[@pone.0230576.ref026]\]. It is difficult to compare the results of this work with others published in terms of severity, seriousness and causality, since ADRs classifications employed in the literature show considerable heterogeneity \[[@pone.0230576.ref033],[@pone.0230576.ref034]\]. In this study, the NOM-220-SSA1-2012 classification of severity was modified because it is ambiguous and generated uncertainty in the assessment. For example, to classify ADRs as moderate and severe, the parameter of requiring or prolonging hospitalization due to an ADR is not considered, while in mild reactions, the fact that hospitalization is not required or prolonged is explicitly mentioned. In addition, it does not describe where to include ADRs that only require suspect drug discontinuation and no treatment. To facilitate the comparison of results with other studies, it is important for NOM-220 future versions to be revised and for other more objective scales used by other authors to assess severity, such as the Hartwig SC et al. scale, to be included \[[@pone.0230576.ref043]\]. NOM-220 uses the definition of seriousness of the International Conference on Harmonization \[[@pone.0230576.ref001]\] that has already been used by other authors \[[@pone.0230576.ref044]\]. In pharmacovigilance, the measurement of causality is essential to establish whether there is a causal relationship between any clinical manifestation and a medication, and to assess it, different algorithms have therefore been proposed \[[@pone.0230576.ref045]\]. In this work, causality was determined with the Naranjo algorithm \[[@pone.0230576.ref027]\], since it is the most widely used in pediatric studies \[[@pone.0230576.ref034]\] and because it is less prone to subjective variations \[[@pone.0230576.ref046]\]; however, there are authors who suggest that the Naranjo algorithm is not a consistent tool for the assessment of ADRs in hospital environments \[[@pone.0230576.ref047]\]. Most ADRs were probable and possible, which could be explained by the fact that 44.5% of ADRs were of oncological origin (febrile neutropenia) and, to analyze them with the Naranjo algorithm, it is necessary to consider: **a)** that in chemotherapy regimens, other drugs are administered that can also explain the observed ADRs as, for example, febrile neutropenia and **b)** it cannot be assessed whether ADRs improve when the treatment is interrupted, since the manifestations occur days after chemotherapy is administered as, for example, febrile neutropenia. On the other hand, in most cases it was not feasible to assess re-administration of the drug due to the limitations inherent to treatments and ethical constraints, which explains that only 2.1% of ADRs were definite. In this work, ADRs were described by seriousness because NOM-220-SSA1-2012 uses this criterion to establish the regulatory obligations of participants in pharmacovigilance activities in Mexico \[[@pone.0230576.ref026]\].

The most common serious ADRs were febrile neutropenia and sepsis, which can be explained by the fact that **a)** they are the most commonly occurring ADRs because patients who are mainly treated at HIMFG have diagnoses of oncological nature \[[@pone.0230576.ref024]\] or **b)** these are the reactions doctors reported more frequently to the CIF owing to their clinical relevance. Abnormal electrolytes was the non-serious ADR that occurred most often, which can largely be explained by the fact that it is the ADR most frequently attributed to furosemide \[[@pone.0230576.ref048]\], which is the most commonly administered drug in the non-serious ADRs group **(**[S2 Table](#pone.0230576.s003){ref-type="supplementary-material"}**)**.

The frequency of drug-related deaths identified in this study is 1.1%, which is consistent with that reported in the literature (0.1% to 13%) \[[@pone.0230576.ref032]\]; however, it is important to consider that there is wide variability in published values ​​and that, as previously mentioned, ADR underreporting at HIMFG is 93.9% \[[@pone.0230576.ref038]\] and, thus, the problem might be underestimated. Antineoplastic and immunomodulating agents use and febrile neutropenia occurred more commonly in patients whose outcome was drug-related death, which has already been widely studied in patients on cancer treatment \[[@pone.0230576.ref049],[@pone.0230576.ref050]\]. On the other hand, 0.7% of patients recovered with some sequel, which is consistent with previous reports in the literature \[[@pone.0230576.ref051]\]. Up to 70.3% of ADRs resulted in hospital admission, which can be attributed to the fact that the main diagnosis of the patients in this study is of oncological nature and, in these patients, febrile neutropenia and sepsis are a cause of admissions to the emergency department \[[@pone.0230576.ref010]\].

As for the main groups of drugs that caused serious ADRs, it was the Antineoplastic and immunomodulating agents (81.2%), Cardiovascular system (8.0%) and Nervous system (4.2%) groups, while those that caused non-serious ADRs were from the Cardiovascular system (34.9%), Antiinfectives for systemic use (21.8%) and Nervous system (16.5%) groups. This is in contrast with reports in the literature, since according to the Uppsala Monitoring Center \[[@pone.0230576.ref016]\], the ATC groups of drugs that are associated with a higher frequency of ADRs in children are the Antiinfectives for systemic use (33%), Nervous system (28%) and Dermatologicals (12%) groups. However, in pediatric hospitals, the classes of drugs associated with ADRs according to severity level include those that have been reported to be of "low severity" such as antibiotics (34%), narcotic analgesics (11%) and anticonvulsants (10%), while antineoplastic agents (21%), anticonvulsants (19%) and narcotic analgesics (14%) are considered to be of "high severity" \[[@pone.0230576.ref052]\]. Despite methodological differences between the studies, the therapeutic groups that were associated with ADRs showed some contrasts between countries with the same National Income Level Per Capita as Mexico such as Malaysia, Colombia, Cuba and Uruguay \[[@pone.0230576.ref053]\]. In hospitalized children of Colombia, the three main medication groups that were associated with ADRs are Antibiotics, Respiratory system and Systemic hormonal preparations \[[@pone.0230576.ref054]\], while in Uruguay, the main groups were Antiinfectives for systemic use, Antiepileptics and Analgesics \[[@pone.0230576.ref055]\]. In both publications, Antineoplastic and immunomodulating agents were not reported to be associated with ADRs. On the other hand, in Cuban hospitalized children, the three main medication groups associated with ADRs were Antimicrobials, Non-opioid analgesics and Antineoplastic \[[@pone.0230576.ref056]\]. In hospitalized children of Malaysia, the most common were the Antiinfectives for systemic use, Nervous system and Respiratory system groups, while Antineoplastic and immunomodulating agents were at twelfth place \[[@pone.0230576.ref057]\].

Study limitations {#sec027}
-----------------

The limitations of the study that should be considered when interpreting the results include:

-   ADR underreporting

-   Barriers to identify some ADRs due to patients' own characteristics; for example, headache caused by caffeine administration in neonates

-   The explanation of some ADRs signs and symptoms can also be attributed to the highly complex diseases of HIMFG patients

-   The findings here encountered cannot be generalized to other Mexican pediatric hospitals

Conclusion {#sec028}
==========

The safety information of the drugs that are marketed in the area of pediatrics in the national market is limited, and the need to strengthen Pharmacovigilance programs in hospitals is therefore evident. This is the first study in Mexico that provides an estimate of the impact of ADRs in hospitalized pediatric patients, which is highly important because the epidemiology of drug usage in children is different between countries. On the other hand, it contributes to the understanding of prescription patterns in Mexican pediatric hospitals, which should help the development of interventions to minimize the impact of ADRs on children.
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